ArticleOncotarget2012
Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity.
Article in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division.Nature communications · 2022Article
- MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.Oncology letters · 2021Article
- MCTS1 promotes invasion and metastasis of oral cancer by modifying the EMT process.Annals of translational medicine · 2021Article
- DENR promotes translation reinitiation via ribosome recycling to drive expression of oncogenes including ATF4.Nature communications · 2020Article
- Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.Experimental hematology & oncology · 2020Article
- MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.Molecular cancer · 2019Article
- SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer.Oncology reports · 2019Article
- Article
- Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression.Oncogenesis · 2017Article
- Review
- Network-Based Integration of Disparate Omic Data To Identify "Silent Players" in Cancer.PLoS computational biology · 2015Article
- Profiling of differentially expressed genes in sheep T lymphocytes response to an artificial primary Haemonchus contortus infection.Parasites & vectors · 2015Article
- Could the eIF2α-Independent Translation Be the Achilles Heel of Cancer?Frontiers in oncology · 2015Review
- Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation.Oncogene · 2014Article
- Selective anti-cancer agents as anti-aging drugs.Cancer biology & therapy · 2013Article
- Advances in targeting signal transduction pathways.Oncotarget · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of Shc adaptor proteins is associated with mitogenesis, carcinogenesis and metastasis. Multiple copies in T-cell malignancy 1 (MCT-1) oncoprotein promotes cell proliferation, survival and tumorigenic effects. Our current data show that MCT-1 is a novel regulator of Shc-Ras-MEK-ERK signaling and MCT-1 is significantly co-activated with Shc gene in human carcinomas. The knockdown of MCT-1 enhances apoptotic cell death accompanied with the activation of caspases and cleavage of caspase substrates under environmental stress. The cancer cell proliferation, chemo-resistance and tumorigenic capacity are proved to be effectively suppressed by targeting MCT-1. Accordingly, an important linkage between MCT-1 oncogenicity and Shc pathway in tumor development has now been established. Promoting MCT-1 expression by gene hyperactivation may be recognized as a tumor marker and MCT-1 may serve as a molecular target of cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.